The oculocerebrorenal syndrome gene product is a 105-kD protein localized to the Golgi complex.

Por Olivos-Glander, I M, Jänne, P A, Nussbaum, R L
Publicado em 1995

Isolation of a candidate gene for choroideremia.

Por Merry, D E, Jänne, P A, Landers, J E, Lewis, R A, Nussbaum, R L
Publicado em 1992

Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy

Por Nishino, M., Jackman, D.M., DiPiro, P.J., Hatabu, H., Jänne, P.A., Johnson, B.E.
Publicado em 2014

Two ornithine decarboxylase mRNA species in mouse kidney arise from size heterogeneity at their 3' termini.

Por Hickok, N J, Seppänen, P J, Kontula, K K, Jänne, P A, Bardin, C W, Jänne, O A
Publicado em 1986

Exclusion of linkage between the human apolipoprotein B gene and abetalipoproteinemia.

Por Huang, L S, Jänne, P A, de Graaf, J, Cooper, M, Deckelbaum, R J, Kayden, H, Breslow, J L, Decklebaum, R J
Publicado em 1990

Functional overlap between murine Inpp5b and Ocrl1 may explain why deficiency of the murine ortholog for OCRL1 does not cause Lowe syndrome in mice.

Por Jänne, P A, Suchy, S F, Bernard, D, MacDonald, M, Crawley, J, Grinberg, A, Wynshaw-Boris, A, Westphal, H, Nussbaum, R L
Publicado em 1998

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer

Por Flores, L M, Kindelberger, D W, Ligon, A H, Capelletti, M, Fiorentino, M, Loda, M, Cibas, E S, Jänne, P A, Krop, I E
Publicado em 2010

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells

Por Tanizaki, J, Okamoto, I, Takezawa, K, Sakai, K, Azuma, K, Kuwata, K, Yamaguchi, H, Hatashita, E, Nishio, K, Janne, P A, Nakagawa, K
Publicado em 2012

Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway

Por Cortot, A.B., Repellin, C.E., Shimamura, T., Capelletti, M., Zejnullahu, K., Ercan, D., Christensen, J. G., Wong, K.-K., Gray, N. S., Jänne, P.A.
Publicado em 2012

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumo...

Por Kris, M. G., Camidge, D. R., Giaccone, G., Hida, T., Li, B. T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M. E., Goldberg, Z., Jänne, P. A.
Publicado no Ann Oncol (2015)

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients

Por Cappuzzo, F., Jänne, P. A., Skokan, M., Finocchiaro, G., Rossi, E., Ligorio, C., Zucali, P. A., Terracciano, L., Toschi, L., Roncalli, M., Destro, A., Incarbone, M., Alloisio, M., Santoro, A., Varella-Garcia, M.
Publicado em 2009

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

Por Cappuzzo, F, Varella-Garcia, M, Finocchiaro, G, Skokan, M, Gajapathy, S, Carnaghi, C, Rimassa, L, Rossi, E, Ligorio, C, Di Tommaso, L, Holmes, A J, Toschi, L, Tallini, G, Destro, A, Roncalli, M, Santoro, A, Jänne, P A
Publicado em 2008

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients

Por Koivunen, J P, Kim, J, Lee, J, Rogers, A M, Park, J O, Zhao, X, Naoki, K, Okamoto, I, Nakagawa, K, Yeap, B Y, Meyerson, M, Wong, K-K, Richards, W G, Sugarbaker, D J, Johnson, B E, Jänne, P A
Publicado em 2008

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

Por Jänne, P A, Smith, I, McWalter, G, Mann, H, Dougherty, B, Walker, J, Orr, M C M, Hodgson, D R, Shaw, A T, Pereira, J R, Jeannin, G, Vansteenkiste, J, Barrios, C H, Franke, F A, Crinò, L, Smith, P
Publicado no Br J Cancer (2015)

SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced o...

Por Soria, J -C, Fülöp, A, Maciel, C, Fischer, J R, Girotto, G, Lago, S, Smit, E, Ostoros, G, Eberhardt, W E E, Lishkovska, P, Lovick, S, Mariani, G, McKeown, A, Kilgour, E, Smith, P, Bowen, K, Kohlmann, A, Carlile, D J, Jänne, P A
Publicado no Ann Oncol (2017)

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)(†)

Por Blumenschein, G. R., Smit, E. F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N. H., Kim, J.-H., Mazieres, J., Kim, S.-W., Baas, P., Rappold, E., Redhu, S., Puski, A., Wu, F. S., Jänne, P. A.
Publicado no Ann Oncol (2015)

Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer

Por Vaishnavi, A., Capelletti, M., Le, A.T., Kako, S., Butaney, M., Ercan, D., Mahale, S., Davies, K.D., Aisner, D.L., Pilling, A.B., Berge, E.M., Kim, J., Sasaki, H., Park, S., Kryukov, G., Garraway, L.A., Hammerman, Peter S., Haas, J., Andrews, S.W., Lipson, D., Stephens, P.J., Miller, V.A., Varella-Garcia, M., Jänne, P.A., Doebele, R.C.
Publicado em 2013